

# Premature Ejaculation Market - Global Outlook and Forecast 2017 - 2022

<https://marketpublishers.com/r/P563ECA2191EN.html>

Date: November 2017

Pages: 138

Price: US\$ 3,500.00 (Single User License)

ID: P563ECA2191EN

## Abstracts

Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals and Allergan are the leading companies dominating the premature ejaculation market. The global premature ejaculation (PE) market is expected to cross \$1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016-2022. A high burden of PE prevalence and associated chronic condition, which can, in turn, poses as a high-risk factor for the occurrence of this disease is the key market driver for the premature ejaculation market in both developing and developed countries. Regionally, the US is the main contributor to the global PE market. Despite the absence of PE drug in the US, the market in North America retains dominant share because of wide accessibility to PE off-labels and OTC drugs. In terms of route of administration, the oral drugs segment contributes a dominant share of nearly three-fourths of the global market.

## Report Timeline

Base Year: 2016

Forecast Year: 2017-2022

Major vendors profiled in the report are as following:

Innovus Pharma

Plethora Solutions

Absorption Pharmaceuticals

Allergan

Other prominent vendors include Menarini, GlaxoSmithKline, Ixchelsis, Dong-A Pharmaceutical, NeuroHealing Pharmaceuticals.

## **SCOPE OF THE REPORT**

The report considers the present scenario of the global premature ejaculation market and its in-depth analysis for the period 2017–2022. It includes a detailed study of growth drivers, trends, and restraints. The report also profiles the leading vendors in the market and other key vendors.

The report provides the analysis of key segments of the market by route administration, mechanism of action, geography, and vendors. It provides a detailed analysis of revenue from various segments:

Route Administration

Topical therapies

Oral therapy

Mechanism of Action

SSRI

PDE5 inhibitors

Ester/Amide anesthetics

Geography

APAC

Europe

Latin America

MEA

North America

Major trends, drivers, and restraints for each geography are included in the report.

Premature ejaculation (PE) is a male sexual dysfunction, which is characterized by the inability to delay ejaculation for more than one minute after penetration or sexual stimulation. The condition is associated with uncontrolled ejaculation either before or shortly after sexual penetration, or with minimal sexual stimulation.

The global premature ejaculation market is expected to cross \$1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016-2022. Increasing disease awareness, growing patient willingness to seek pharmaceutical therapy assistance for disease management and increasing presence of favorable guidelines, which recommended the use of drugs as first-line therapy for treatment of PE, will augment market prospects during the forecast period.

The report provides a holistic view of the global premature ejaculation market, the companies involved in the market, and the factors driving its growth. The report also provides information about the latest trends that are likely to become strong market driving forces over the next five years. This report also provides the Porter's Five Forces analysis along with a description of each force and its impact on the market. Further, the report also provides complete value chain analysis of the global market.

### Premature Ejaculation Market Dynamics

Emphasis on clinical progress of love hormone receptor antagonists to drive the market growth

Increase in prevalence of chronic diseases, low-effectiveness of non-pharmacological treatment, and a wide accessibility to premature ejaculation OTC drugs and generic off-label drugs are the prime factors that are going to escalate the market growth during the forecast period. Furthermore, pharmaceutical advances in PE drug formulation technology, emphasis on clinical progress of love hormone receptor antagonists, and

launch of premature ejaculation treatment awareness campaigns are the latest trends that are likely to positively impact the market. The report also provides the key restraints of the market.

### Premature Ejaculation Market: Segmental Overview

The amide anesthetics segment is the fast-growing segment in terms of mechanism of action.

The oral drug segment to remain the dominant market in terms of route of administration. The topical PE drugs market is expected to witness growth at a higher pace than the oral PE drugs market. However, the oral PE drugs market is likely to retain its market share until the end of the forecast period.

In terms of mechanism of action (MOA), the global PE market broad segments include SSRIs, PDE5 inhibitors, and amide anesthetics. In 2016, the SSRIs segment dominated the market. This segment is anticipated to retain its dominance till the end of forecast period. The amide anesthetics segment, which occupied low share in 2016, is anticipated to witness higher growth than the other drug MOAs segment during the period 2016-2022.

### Premature Ejaculation Market: Geographical Analysis

North America to remain the largest market followed by Europe

The premature ejaculation market in North America is the largest due to high prevalent PE population. The US occupies approximately 90% of the PE market in North America due to the high population density and comparably higher utilization of off-label and OTC PE products. Similarly, the UK, Germany, France, Spain, and Italy are the leading markets for PE therapies in the European region. The market in APAC is likely to witness the highest growth rate during the forecast period. A significant increase in PE incidence due to growing burden of chronic conditions, which, in turn, is associated with the high risk of PE occurrence is expected to boost the market growth in this region. The prevalence of PE in the Middle East countries and Latin America is estimated to be lowest than other regions. The market, however, is anticipated to witness a moderate growth rate in these regions.

## Contents

### **1 RESEARCH METHODOLOGY**

### **2 RESEARCH OBJECTIVES**

### **3 RESEARCH PROCESS**

### **4 REPORT COVERAGE**

#### 4.1 Market Definition

#### 4.2 Base Year

#### 4.3 Scope of Study

##### 4.3.1 Market Segmentation by Route of Administration

##### 4.3.2 Market Segmentation by Mechanism of Action

##### 4.3.3 Market Segmentation by Geography

### **5 REPORT ASSUMPTIONS & CAVEATS**

#### 5.1 Currency Conversion rate

#### 5.2 Market Derivation

### **6 MARKET AT A GLANCE**

### **7 INTRODUCTION**

#### 7.1 Definition Of Premature Ejaculation

#### 7.2 Disease Overview

#### 7.3 CLASSIFICATION OF Premature Ejaculation

##### 7.3.1 Lifelong PE

##### 7.3.2 Acquired PE

##### 7.3.3 Variable PE

##### 7.3.4 Subjective EjD

#### 7.4 Symptoms Of Premature Ejaculation (Pe)

#### 7.5 Aetiology OF Premature Ejaculation

##### 7.5.1 Physiological Factors

##### 7.5.2 Biological Factors

##### 7.5.3 Genetic Factors

##### 7.5.4 Co-morbidity

## 7.6 Epidemiology

## **8 ISSN GUIDELINES ON PE**

### 8.1 Disease Assessment

#### 8.1.1 Patient History

#### 8.1.2 Physical Examination

#### 8.1.3 Assessment Instruments

### 8.2 Treatment

#### 8.2.1 Physiological Therapy

#### 8.2.2 Behavioral Techniques

#### 8.2.3 Pharmacological Treatment

## **9 CLINICAL TRIAL LANDSCAPE**

### 9.1 Overview

#### 9.1.1 Trial Subjects Selection Criteria

#### 9.1.2 Trial Design Considerations

#### 9.1.3 Trial Data Evaluation Considerations

### 9.2 Clinical Trial EndPoints

## **10 PIPELINE LANDSCAPE**

### 10.1 Overview

### 10.2 Key Pipeline Drug Candidates

### 10.3 Dormant/Terminated/Withdrawn Drug Candidates

### 10.4 Key Product Profiles

#### 10.5 Epelsiban

##### 10.5.1 Overview

##### 10.5.2 Product Profile

##### 10.5.3 Future Outlook

#### 10.6 IX-01

##### 10.6.1 Overview

##### 10.6.2 Product Profile

##### 10.6.3 Future Outlook

#### 10.7 DA-8031

##### 10.7.1 Overview

##### 10.7.2 Product Profile

##### 10.7.3 Future Outlook

## **11 MARKETED PRODUCTS LANDSCAPE**

11.1 overview

11.2 Recommended Marketed Drugs

## **12 MARKET DYNAMICS**

12.1 Market Growth Enablers

12.1.1 Increase in Prevalence of Chronic Diseases

12.1.2 Low-effectiveness of Non-pharmacological PE Treatment

12.1.3 High Unmet Need

12.1.4 Wide Accessibility to PE OTC Drugs and Generic Off-label Drugs

12.1.5 YOY Impact of Market Enablers

12.2 Market Growth Restraints

12.2.1 Low Treatment Seeking Patient Pool

12.2.2 Associated Adverse Effects of PE Drugs

12.2.3 Clinical Trial Withdrawals/Terminations

12.2.4 YOY Impact of Market Restraints

12.3 Market Opportunities & Trends

12.3.1 Advances in PE Drug Formulation Technologies

12.3.2 Emphasis on Clinical Progress of Love Hormone Receptor Antagonists

12.3.3 Launch of PE Awareness Campaigns

12.3.4 YOY Impact of Trends and Opportunities

## **13 GLOBAL PREMATURE EJACULATION MARKET**

13.1 market Overview

13.2 Market Size & Forecast

13.3 Porter's Five Forces Analysis

13.3.1 Threat of New Entrants

13.3.2 Bargaining Power of Suppliers

13.3.3 Bargaining Power of Buyers

13.3.4 Threat of Substitutes

13.3.5 Competitive Rivalry

## **14 PREMATURE EJACULATION MARKET- BY ROUTE OF ADMINISTRATION**

14.1 Segment Overview

14.2 PE ORAL THERAPY Market

14.3 PE TOPICAL THERAPY MARKET

## **15 PREMATURE EJACULATION MARKET - BY MECHANISM OF ACTION**

15.1 Segment Overview

15.2 SSRI PE Therapy Market

15.2.1 Market Size & Forecast

15.3 PDE5i PE Therapy Market

15.3.1 Market Size & Forecast

15.4 AMIDE/ESTER ANESTHETIC PE Therapy Market

15.4.1 Market Size & Forecast

## **16 PREMATURE EJACULATION MARKET BY GEOGRAPHY**

16.1 Market Overview

## **17 NORTH AMERICA: PREMATURE EJACULATION MARKET**

17.1 Market Overview

17.2 Market Size & Forecast

17.3 Key Countries

17.3.1 US: Market Size & Forecast

17.3.2 Canada: Market Size & Forecast

17.4 Leading Trends, Enablers, and Restraints

## **18 EUROPE: PREMATURE EJACULATION MARKET**

18.1 Market Overview

18.2 Market Size & Forecast

18.3 Key Countries

18.3.1 Germany: Market Size & Forecast

18.3.2 UK: Market Size & Forecast

18.3.3 France: Market Size & Forecast

18.3.4 Spain and Italy: Market Size & Forecast

18.4 Leading Trends, Enablers, and Restraints

## **19 APAC: PREMATURE EJACULATION MARKET**



- 19.1 Market Overview
- 19.2 Market Size & Forecast
- 19.3 Key Countries
  - 19.3.1 Japan: Market Size & Forecast
  - 19.3.2 Australia: Market Size & Forecast
  - 19.3.3 China and India: Market Size & Forecast
- 19.4 Leading Trends, Enablers, and Restraints

## **20 LATIN AMERICA: PREMATURE EJACULATION MARKET**

- 20.1 Market Overview
- 20.2 Market Size & Forecast
- 20.3 Major Trends, Enablers, and Restraints

## **21 MEA: PREMATURE EJACULATION MARKET**

- 21.1 Market Overview
- 21.2 Market Size & Forecast
- 21.3 Major Trends, Enablers, and Restraints

## **22 COMPETITIVE LANDSCAPE**

- 22.1 Strategic Recommendation for Market Participants

## **23 KEY COMPANY PROFILES**

- 23.1 Innovus Pharmaceuticals INC.
  - 23.1.1 Strength Assessment
  - 23.1.2 Strategy Assessment
  - 23.1.3 Opportunity Assessment
- 23.2 Plethora Solutions Holdings PLC
  - 23.2.1 Strength Assessment
  - 23.2.2 Strategy Assessment
  - 23.2.3 Opportunity Assessment
- 23.3 Absorption Pharmaceuticals LLC
  - 23.3.1 Strength Assessment
  - 23.3.2 Strategy Assessment
  - 23.3.3 Opportunity Assessment
- 23.4 Allergen PLC

- 23.4.1 Strength Assessment
- 23.4.2 Strategy Assessment
- 23.4.3 Opportunity Assessment

## **24 OTHER PROMINENT COMPANIES**

- 24.1 Menrnani
  - 24.1.1 Strength Assessment
  - 24.1.2 Strategy Assessment
  - 24.1.3 Opportunity Assessment
- 24.2 GlaxoSmithKline plc
  - 24.2.1 Strength Assessment
  - 24.2.2 Strategy Assessment
  - 24.2.3 Opportunity Assessment
- 24.3 Ixchelsis Ltd
  - 24.3.1 Strength Assessment
  - 24.3.2 Strategy Assessment
  - 24.3.3 Opportunity Assessment
- 24.4 DONG-A- Pharmaceuticals Co. Ltd.
  - 24.4.1 Strength Assessment
  - 24.4.2 Strategy Assessment
  - 24.4.3 Opportunity Assessment
- 24.5 NeuroHealing Pharmaceuticals Inc.
  - 24.5.1 Strength Assessment
  - 24.5.2 Strategy Assessment
  - 24.5.3 Opportunity Assessment

## **25 REPORT SUMMARY**

- 25.1 Key Takeaways
- 25.2 Qualitative Summary of Global PRE-Mature Ejaculation Market
- 25.3 Quantitative Summary of Global PRE-Mature Ejaculation Market

## **26 APPENDIX**

- 26.1 List of Abbreviations
- List Of Exhibits
- Exhibit 1 Segmentation of Global PE Market
- Exhibit 2 Market Size Calculation Approach 2016

- Exhibit 3 Classification of PE
- Exhibit 4 Differentiation of Symptoms in PE Sub-types
- Exhibit 5 Common Causative Factors for PE
- Exhibit 6 PE Prevalence Rate across Various Geographical Regions
- Exhibit 7 ISSN Recommended Drug Classes for PE Treatment
- Exhibit 8 PE Treatment Algorithm
- Exhibit 9 Key Considerations of PE Clinical Trials
- Exhibit 10 Key Primary/Secondary Endpoints in PE Clinical Trials
- Exhibit 11 Key Hurdles in Research and Innovation of Breakthrough PE Drugs
- Exhibit 12 Increase in Global Diabetes Prevalence by Region 2015–2040 (Million)
- Exhibit 13 Increase in Global ED Prevalence 1995-2025 (Million)
- Exhibit 14 Increase in Global Prostate Cancer Incidence by Region 2012–2020 (thousand)
- Exhibit 15 Major Drawbacks of Non-pharmacological PE Treatments
- Exhibit 16 PE OTC Drugs Marketing Channels
- Exhibit 17 Major Factors Restricting PE Treatment Rate
- Exhibit 18 Korean Nation-wide Survey Results On Urologists' PE Treatment Rates Per Week (in %) 2012
- Exhibit 19 Key Issues Leading to Clinical Trial Terminations/Withdrawal
- Exhibit 20 Global PE Market 2016–2022 (\$ million)
- Exhibit 21 Five Forces Analysis 2016
- Exhibit 22 Global PE Market by Route of Administration
- Exhibit 23 Percentage Share of Oral and Topical PE Drugs 2016 and 2022
- Exhibit 24 Global PE Market by Route of Administration (\$ million)
- Exhibit 25 Comparison of Growth Rates of Oral and Topical PE Segments
- Exhibit 26 Most Common Oral Therapy Drug Types
- Exhibit 27 Benefits/Drawbacks Summary of Oral PE Drugs
- Exhibit 28 Global PE Oral Therapy Market Size and Forecast (\$ million) 2016–2022
- Exhibit 29 Available Topical Forms of PE Topical Therapies
- Exhibit 30 Benefits/Drawbacks Summary of Topical PE Drugs
- Exhibit 31 Global PE Topical Therapy Market Size and Forecast (\$ million)
- Exhibit 32 Global PE Market by Mechanism of Action
- Exhibit 33 Percentage Share of SSRIs, PDE5is, and Amide Anesthetics
- Exhibit 34 Global PE Market Lucrativeness by Mechanism of Action
- Exhibit 35 Global PE Market by Mechanism of Action (\$ million)
- Exhibit 36 Comparison of Varying Efficacy of Off-label SSRIs
- Exhibit 37 Global SSRI PE Drugs Market Size and Forecast (\$ million)
- Exhibit 38 Major PDE5i Drug Brands as Off-label PE Medications
- Exhibit 39 Global PDE5i PE Therapy Market Size and Forecast (\$ million)

- Exhibit 40 Common Active Ingredients in Amide Anesthetic PE Formulations
  - Exhibit 41 Global PDE5i PE Therapy Market Size and Forecast (\$ million)
  - Exhibit 42 Mode of Action of SSRIs
  - Exhibit 43 Global PE Market by Geography
  - Exhibit 44 Global PE Market by Geography (\$ million)
  - Exhibit 45 Market Revenue Growth Rates Comparison by Geography
  - Exhibit 46 Global PE Market Lucrativeness by Geography 2022
  - Exhibit 47 PE Market in North America by Country 2016
  - Exhibit 48 Prevalence of PE in North America
  - Exhibit 49 PE Market in North America 2016–2022 (\$ million)
  - Exhibit 50 PE Market in US 2016–2022 (\$ million)
  - Exhibit 51 PE Market in Canada 2016–2022 (\$ million)
  - Exhibit 52 Key PE Market Dynamics in North America
  - Exhibit 53 PE Market in Europe by Country 2016
  - Exhibit 54 Prevalence Trend of Prostate Cancer Holding High Associated Risk for PE Incidence in Europe 2012–2020 (thousand)
  - Exhibit 55 PE Market in Europe (\$ million)
  - Exhibit 56 PE Market in Germany 2016–2022 (\$ million)
  - Exhibit 57 PE Market in UK (\$ million)
  - Exhibit 58 PE Market in France (\$ million)
  - Exhibit 59 PE Market in Italy (\$ million)
  - Exhibit 60 PE Market in Spain (\$ million)
  - Exhibit 61 Key PE Market Dynamics in Europe
  - Exhibit 62 PE Market in APAC (\$ million)
  - Exhibit 63 PE Market in Japan 2016–2022 (\$ million)
  - Exhibit 64 PE Market in Australia (\$ million)
  - Exhibit 65 PE Market in China (\$ million)
  - Exhibit 66 PE Market in India (\$ million)
  - Exhibit 67 Key PE Market Dynamics in APAC
  - Exhibit 68 PE Market in Latin America (\$ million)
  - Exhibit 69 Key PE Market Dynamics in Latin America
  - Exhibit 70 PE Market in MEA 2016–2022 (\$ million)
  - Exhibit 71 Key PE Market Dynamics in Latin America
  - Exhibit 72 Strategic Recommendation for Market Participants
- TABLES**
- Table 1 Key Geographies Definition
  - Table 2 Key Caveats
  - Table 3 Currency Conversion 2013?2016
  - Table 4 Early Definitions of Premature Ejaculation

Table 5 Summary of PE Epidemiology Studies

Table 6 Recommended/Optional Questions to Establish Diagnosis and Treatment of PE

Table 7 Summary of PE Validated Questionnaires

Table 8 Summary of Commonly Recommended PE Drugs

Table 9 Key Pipeline PE Drug Molecules

Table 10 Key Dormant/Terminated/Withdrawn PE Pipeline Drug Molecules

Table 11 Epelsiban Product Profile

Table 12 IX-01 Product Profile

Table 13 DA-8031 Product Profile

Table 14 Recommended Drugs for PE Treatment

Table 15 Major Unmet Need in PE Market

Table 16 YOY Impact of Market Enablers 2016–2022

Table 17 Key Terminated/Withdrawn Investigational PE Drugs

Table 18 YOY Impact of Market Restraints 2016–2022

Table 19 Marketed PE Drugs with Meter-Dose Delivery Systems

Table 20 Pipeline Oxytocin Receptor Antagonists

Table 21 YOY Impact of Trends and Opportunities 2016–2022

Table 22 Global PE Market by Route of Administration 2016–2022 (\$ million)

Table 23 Key Topical Therapy PE Drugs by Type of Formulation

Table 24 Global PE Market by Mechanism of Action 2016–2022 (\$ million)

Table 25 Commonly Used Topical PE OTC Ester/Amide Anesthetic

Table 26 Global PE Market by Geography 2016–2022 (\$ million)

Table 27 Key PE Campaigns Launched in Europe

Table 28 Competitive Structure Analysis of Global PE Market 2016

Table 29 Therapeutic Area and Products of Innovus

Table 30 Qualitative Summary of Global PE Market

Table 31 Quantitative Summary of Global PE Market by Geography (\$ million)

Table 32 Quantitative Summary of Global PE Market by Geography (Revenue %)

Table 33 Quantitative Summary of Global PE Market by Route of Administration (\$ million)

Table 34 Quantitative Summary of Global PE Market by Mechanism of Action (\$ million)

## I would like to order

Product name: Premature Ejaculation Market - Global Outlook and Forecast 2017 - 2022

Product link: <https://marketpublishers.com/r/P563ECA2191EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P563ECA2191EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970